# A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC

> **NCT04325698** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 8 (actual)

## Conditions studied

- Advanced Non-squamous NSCLC

## Interventions

- **DRUG:** PF-06439535 (CN)
- **DRUG:** Bevacizumab-EU
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT04325698
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-11
- **Primary completion:** 2021-05-10
- **Final completion:** 2021-05-10
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** The study was terminated as part of the decision by Pfizer to halt its biosimilars programs in China.
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04325698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04325698, "A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04325698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*